# CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

> **NCT06399419** · PHASE1 · RECRUITING · sponsor: **Osel, Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Advanced Clear Cell Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Advanced Sarcomatoid Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Sarcomatoid Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **BIOLOGICAL:** CBM588 Capsules
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT06399419
- **Lead sponsor:** Osel, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2026-10-19
- **Final completion:** 2026-10-19
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06399419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06399419, "CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06399419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*